Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases

BACKGROUND AND AIMS: Despite proven clinical efficacy of vedolizumab (VDZ) for inducing and maintaining remission in patients with Crohn’s disease (CD) and ulcerative colitis (UC), subgroups of patients have no therapeutic benefit from anti-α4β7 integrin therapy with VDZ. Within this study, we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Rath, Timo, Billmeier, Ulrike, Ferrazzi, Fulvia, Vieth, Michael, Ekici, Arif, Neurath, Markus F., Atreya, Raja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090141/
https://www.ncbi.nlm.nih.gov/pubmed/30131801
http://dx.doi.org/10.3389/fimmu.2018.01700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090141/
https://www.ncbi.nlm.nih.gov/pubmed/30131801
http://dx.doi.org/10.3389/fimmu.2018.01700

Ejemplares similares